in Cancer Patients Receiving Chemotherapy: Seroprevalence and Interferon Gamma Level

is an opportunistic parasite causing life-threatening diseases in immune-compromised patients. The purpose of the study is to determine the seroprevalence of in chemotherapy receiving cancer patients in relation to different types of malignancies, and to estimate the level of interferon gamma in seropositive and seronegative cancer patients and healthy controls. Anti- IgG and IgM antibodies, and interferon gamma were analyzed in 120 cancer patients receiving chemotherapy (60 having hematological malignancies and 60 with solid organ tumors) and 60 healthy controls using ELISA method. (IgG and IgM) were determined in (66.7% and 9.2%) of the cancer group compared to (33.3% and 6.7%) of the control group with statistical significance only in IgG seropositivity ( < 0.001, OR = 4). Patients with hematological malignancies had higher IgG seropositivity than solid organ tumors (40% vs 26.7%). The difference between the groups was statistically significant ( = 0.002, OR = 3.5). Median level of interferon gamma was in the same range between cancer patients and control group. However, it was highly elevated in seropositive (76 pg/ml) than seronegative (44.5 pg/ml) cases with statistical significance ( < 0.001). infection remains a major threat to cancer patients and still needs proper screening, diagnosis and treatment.